The dual-action agent LCZ696 blocks the angiotensin II receptor (via a valsartan moiety) and inhibits neprilysin (via an AHU377 moiety). In a phase II trial, this drug “demonstrated superior ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

Published in the scientific journal Science Signaling on August 6, the study examines dopamine's role in promoting the production of neprilysin, an enzyme that can break down the harmful plaques ...

High blood pressure, or hypertension, is a common condition that affects millions of people globally. It significantly ...

Two posters highlighted the effects of sacubitril/valsartan (Entresto; Novartis) on key biomarkers and cardiac function in ...

For individuals with heart failure with reduced ejection fraction (HFrEF), substantial mortality benefits would result from ...

Treatment strategies have not been well established for thrombotic microangiopathy associated with malignant hypertension.

History of ACEI-associated or other angioedema. Anuria. Sulfonamide allergy. Concomitant neprilysin inhibitors (eg, sacubitril); do not administer benazepril/HCT within 36hrs of switching to or ...

20.4 million individuals for angiotensin receptor neprilysin inhibitors treatment; 12.2 million individuals for mineralocorticoid receptor antagonists treatment; and 21.2 million for SGLT2 ...

ARBs and ARNIs. Angiotensin 2 receptor blockers (ARBs) and angiotensin receptor-neprilysin inhibitors (ARNIs) reduce blood pressure by keeping your blood vessels from constricting. They’re ...

Then we have the ACE and ARBs, the lisonopril and losartans. Basically, now, there's Entresto, which is a combination of a neprilysin inhibitor and an ARB. So that is the go-to now for a lot of ...